BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Doravirine/islatravir (Idvynso) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Doravirine/islatravir (Idvynso)\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04776252-10993@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20290529
DTEND;VALUE=DATE:20290530
SUMMARY:Doravirine/islatravir (Idvynso): Phase 3 readout est. (NCT04776252)
DESCRIPTION:Doravirine/islatravir (Idvynso)\, phase 3\, HIV.\nStudy: Open-l
 abel\, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Part
 icipants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-0
 33)\nEstimated primary completion: 29 May 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/doravirine-islatravir-idvynso#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04776252
URL:https://assetmemo.bio/drug/doravirine-islatravir-idvynso#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
